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Abstract
Introduction: In early rheumatoid arthritis (RA), low-dose oral prednisone (PDN) co-medication yields better clinical
results than monotherapy with disease-modifying anti-rheumatic drugs (DMARDs). In addition, ultrasonography (US)
evaluation reveals rapid and significant effects of glucocorticosteroids on subclinical synovitis. No data currently
exist that examine the clinical and US results offered by glucocorticoid co-medication over DMARD monotherapy
in early RA patients.
Methods: Two hundred and twenty patients with early RA (< 1 year from clinical onset) were treated according to
a low disease activity (LDA) targeted step-up protocol including methotrexate (MTX) and, in the active treatment
arm, low-dose (6.25 mg/day) oral PDN over 12 months. Clinical disease activity measures were collected at
baseline, 2, 4, 6, 9 and 12 months, and US examination of hands was performed at baseline, 6 and 12 months.
Grey-scale and power Doppler (PD) synovitis were scored (0 to 3) for each joint. At 12 months, clinical remission
according to the disease activity score among 28 joints was defined as the clinical outcome, and a total joint PD
Results: Each group included 110 patients with comparable demographic, clinical, laboratory and US characteristics.
At 12 months, the LDA rate was similar in the two groups, whilst the clinical remission rate (risk ratio = 1.61 (95%
confidence interval = 1.08, 2.04)) and PD negativity rate (risk ratio = 1.31 (95% confidence interval = 1.04, 1.64)) were
significantly higher in the MTX+PDN group.
Conclusion: In early RA, despite a similar response rate in terms of LDA, low-dose oral PDN co-medication led to a
higher proportion of clinical remission and PD negativity compared with MTX monotherapy, thus ensuring a better
disease activity control.
Trial registration number: Current Controlled Trials ISRCTN2486111
Introduction
Glucocorticoids (GC) in association with conventional
disease-modifying anti-rheumatic drugs (DMARDs) are
currently recommended for the treatment of rheumatoid
arthritis (RA), after a careful evaluation of the patient’s
risk-to-benefit ratio [1].
In RA, GC show a rapid symptomatic effect on pain
and general well-being and help in controlling objective
signs of inflammation, such as tender and swollen joints
[2-4]. Several studies also support disease-modifying
properties for GC, in terms of prevention of future joint
damage in early RA, both for initial short-term high
dosages followed by step-down schedules and for low-
dose oral therapy regimens [3-8].
On the whole, in clinical trials involving early-onset RA
patients treated with low-dose oral GC in association
with DMARDs, clinical and functional benefits seem to
last only few months after the start of treatment, fading
away thereafter, whilst prevention of structural damage
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may persist over a longer time [5,6]. These studies sug-
gest a sort of dissociation between a short-lasting clinical
improvement and a long-lasting effect on radiographic
progression [9]. Whether the effect on structural damage
is just related to a faster clinical response or may be asso-
ciated with a persistently deeper control of joint inflam-
mation, not fully detectable by clinical tools, is still to be
ascertained.
Sensitive imaging techniques may help in testing these
hypotheses. Recent imaging studies on RA have demon-
strated that the structural progression observed in
patients in clinical remission might be explained by the
persistence of subclinical signs of synovitis detected by
magnetic resonance imaging or ultrasonography (US)
[10]. In particular, power Doppler (PD) US has been
demonstrated to be a valid and reliable tool in detecting
subclinical inflammation in RA, and is believed to be a
measure of activity of joint inflammation [11,12]. At pre-
sent there are no data on the effect of low-dose oral GC
on US-detected synovial inflammation in early RA.
This study aimed to verify the effect of low dosages of
oral prednisone (PDN) on clinical and US outcomes over
12 months of follow-up in patients with recent-onset RA.
For this purpose we randomly allocated patients to
receive low-dose PDN or not within a structured treat-
to-target protocol aiming for low disease activity (LDA)
[13]. Disease activity was prospectively assessed both
clinically and by US.
Methods
Patients
All patients attending the Early Arthritis Clinic of a Uni-
versity Hospital between January 2005 and January 2008,
who were part of a larger cohort study, were eligible for
this open-label randomised clinical trial.
Inclusion criteria were: fulfilment of the American Col-
lege of Rheumatology classification criteria for RA, age >
18 years, symptom duration < 12 months, active disease
according to the disease activity score [14,15]. Exclusion
criteria were: contraindications for steroidal therapy,
including uncontrolled diabetes and previous fragility
osteoporotic fractures.
The local medical ethics committee approved the study
protocol, and all patients gave written informed consent
before study inclusion.
Interventions
All patients in the overall cohort followed a disease-activ-
ity-driven step-up therapeutic protocol aimed at reaching
a state of LDA according to the disease activity score
[15]. In more detail, patients started methotrexate (MTX)
at baseline at a dosage of 10 mg/week; if at the following
visits they did not reach a LDA state, MTX was
increased, if tolerated, to 15 mg/week, then to 20 and
25 mg/week. Patients who did not achieve the target with
the maximum tolerated dosage of MTX started anti-TNF
therapy in association with the ongoing medication, if
not contraindicated.
Given this background therapeutic strategy, patients
were randomised to also receive or not low-dose oral
PDN, starting with 12.5 mg/day for 2 weeks tapered to
6.25 mg/day for the follow-up period, in a once-a-day
morning administration.
Oral folic acid supplementation (5 mg/week) was intro-
duced during treatment with MTX.
During the follow-up, switching to other DMARDs was
permitted in cases of intolerance or toxicity. Concomi-
tant therapy with nonsteroidal anti-inflammatory drugs
and intra-articular injections with GC when required for
refractory monoarticular involvement were allowed. The
patients were also given prophylactic treatment with oral
calcium and vitamin D when not contraindicated.
Clinical assessment
Patients were clinically assessed at baseline and every 2
months during the first 6 months, and then every 3
months thereafter. A four-variable disease activity score
among 28 joints (DAS28) was computed as the disease
activity measure at each visit. Remission according to
DAS28 was defined for values < 2.6 [16]. Clinical remis-
sion was also assessed by the Simplified Disease Activity
Index (SDAI) as recently suggested [17]. For study pur-
poses, clinical evaluation included: number of swollen
and tender joints on 28-joint count, and visual analogue
scale (VAS) scores for pain, global health assessment and
overall disease activity (patient’s global assessment); func-
tional disability was also measured by a self-assessment of
the Italian version of the Health Assessment Question-
naire [18,19]. The erythrocyte sedimentation rate and
C-reactive protein serum levels were measured at each
time point.
Ultrasonographic assessment
US was performed at baseline, 6 and 12 months by a sin-
gle experienced operator unaware of clinical data using a
GE Logiq 9 scanner (General Electrics Medical Systems,
Milwaukee, WI, USA) with a multi-frequency linear array
transducer (10 to 15 MHz), according to the European
League Against Rheumatism guidelines [20].
The US assessment included a limited 12-joint assess-
ment with transverse and longitudinal scanning of the
medial and lateral dorsal views of bilateral wrists (radiocar-
pal, ulnocarpal, radio-ulnar and midcarpal joints) and
metacarpophalangeal joints. PD calibrations were adjusted
at the lowest permissible pulse repetition frequency to
maximise sensitivity and were taken as constant for the
same joint in different patients (dependent on the investi-
gated joint), with a pulse repetition frequency ranging
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from 0.5 to 0.75 MHz. Colour gain was set just below the
level that causes the appearance of noise artefacts. Flow
was demonstrated in two perpendicular planes and con-
firmed by the pulsed-wave Doppler spectrum to exclude
artefacts [21]. Grey-scale (GS) and PD signals were
assigned to each singular joint in accordance with semi-
quantitative scales (0 = normal, 1 = mild, 2 = moderate, 3
= severe), as previously reported [22]. Two cumulative US
joint scores (GS score and PD score) were calculated at
each US assessment as the sum of either GS or PD signal
scores obtained from each joint. US remission was defined
as a PD score of 0 at 12 months, as recently proposed [23].
Each patient evaluation took 20 minutes on average, and
representative images were archived.
Outcomes
Evaluated primary outcomes included: the proportion of
patients achieving clinical remission according to DAS28
(< 2.6) and the proportion of patients achieving PD nega-
tivity (defined as a global PD score of 0) at 12 months
[23]. The combined clinical and US outcome was also
explored, as both DAS28 remission and PD negativity.
Finally, clinical remission was also assessed by the SDAI,
as recently suggested [17].
Sample size, randomisation and blinding
The sample size was defined based on a proportion dif-
ference of 20% with a power of 0.8, allowing for 10% of
attrition. Allocation of patients to treatment was carried
out using an independently generated randomisation list.
Although this is an open-label randomised study, US
was performed by an ultrasonographer who was blinded
to clinical data - including the therapeutic arm - in
order to avoid differential misclassification.
Statistical methods
Intention-to-treat and per-protocol analyses were per-
formed. For intention-to-treat analysis, patients were
analysed according to the treatment group to which they
were originally assigned when at least one single dose of
PDN was taken; while for per-protocol analysis, only
patients who continued the initial treatment were effec-
tively analysed. Clinical quantitative variables are
reported by the median (interquartile range) or by the
mean ± standard deviation, when appropriate. To test
differences between the two groups, the Mann-Whitney
test or the independent-sample t test was used for con-
tinuous variables and the Fisher’s exact test was used for
proportions. As measures of association we used the
mean or median difference from baseline (MD) for con-
tinuous variables, and risk ratios (RRs) and incident rate
ratios for categorical variables. Missing data on outcome
were not imputed and complete case analysis was per-
formed in all cases.
All significance tests were two-tailed at the 0.05 signif-
icance level. All analyses were conducted using Stata
version 11 (StataCorp, College Station, TX, USA).
Results
Patients
A total of 220 patients were enrolled in the study; 110
were randomised to the MTX+PDN group and 110 to
MTX monotherapy. The number of patients lost to the
follow-up is shown in Figure 1. A total of 186 patients
with complete clinical and US follow-up data were
included in the analyses: 90 patients in the MTX arm
and 96 patients in the MTX+PDN arm. Baseline charac-
teristics of patients included in the analyses did not dif-
fer from excluded patients.
At baseline, the subjects assigned to the two therapeu-
tic arms did not significantly differ for demographics,
disease activity and disability indexes (Table 1).
Treatment
Patients in the MTX+PDN group were less likely to
adhere to the protocol, with a RR of 0.82 (95% confidence
interval (CI) = 0.69, 0.96). The main reasons for disconti-
nuation in the GC group (15 patients) were mild side
effects (six patients) and unwillingness to continue GC
therapy (nine patients). Among the 90 completers in the
MTX monotherapy group, five patients started GC medi-
cation because of increased disease activity over time.
The maximum MTX dose was 14.3 ± 4.3 mg/day in the
combination therapy group and 16.1 ± 3.9 mg/day in the
MTX monotherapy group (P = 0.053).
Therapeutic adjustments were made in 101 patients -
57 patients for MTX alone and 44 patients for the MTX
+PDN arm - with a trend toward less therapeutic adjust-
ments in the MTX+PDN group (incident rate ratio =
0.77, 95% CI = 0.50, 1.16; P = 0.19). Sixteen patients in
the MTX group and nine patients in the MTX+PDN
group started anti-TNF therapy before the completion of
12 months of follow-up. At the end of the follow-up, six
and 10 patients, respectively, were still in treatment with
conventional DMARDs despite not achieving LDA; nine
patients denied consent for biologic therapy, three
patients had intercurrent adverse events leading to delay
in treatment steps, and four patients had disease reactiva-
tions at the last visit. Eight patients in the MTX arm and
six patients in the MTX+PDN arm underwent intra-
articular or peri-articular steroid injections.
Clinical response
At the end of the follow-up period, LDA according to the
disease activity score was achieved by 145 out of 186
patients (77.9%), without significant differences between
the two treatment arms: 68 patients (75.5%) in the MTX
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group and 77 patients (80.2%) in the MTX+PDN group
(P = 0.44).
On the whole, subjective (VAS score for pain, VAS score
for patient’s global assessment, VAS score for global health
assessment) and objective (swollen and tender joint
counts) variables, as well as US variables, significantly
improved throughout the follow-up (Figure 2A to 2F).
Comparing the two therapeutic arms, the mean VAS
score for pain (Figure 2A) fell more rapidly in the MTX
+PDN arm, reaching a significant difference between
groups at 2 months (MD = -17.9 (95% CI = -26.4, -9.4),
P < 0.001) and at 4 months (MD = -10.8 (95% CI = -19.1,
-2.5), P = 0.01). This difference was not significant at 6
and 9 months, while it was weakly significant at the end
of the follow-up (MD = -8.8 (95% CI = -17.5, -0.1), P =
0.04). Similarly, the mean swollen joint count (Figure 2B)
fell more rapidly in the MTX+PDN arm, reaching a sig-
nificant mean difference at 2 months (MD = -2.0 (95%
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Figure 1 Flow chart of patients enrolled in the trial. MTX, methotrexate monotherapy; MTX+PDN, methotrexate + prednisone combination
therapy.
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CI = -3.6,-0.3), P = 0.01) and 4 months (MD = -1.9 (95%
CI = -3.6, -0.2), P = 0.02). This difference was not signifi-
cant at 6, 9 and 12 months. No significant differences
were observed for the tender joint count (Figure 2C)
throughout the entire follow-up period. Acute-phase
reactants (erythrocyte sedimentation rate and C-reactive
protein) showed a significantly greater improvement
(Figure 2D,E) in the MTX+PDN group throughout the
entire period of follow-up.
Comparing the two therapeutic arms, the mean DAS28
score (Figure 2F) fell more rapidly in the MTX+PDN
group, while the differences became not statistically signif-
icant throughout the follow-up: the DAS28 MD was -0.69
(95% CI = -1.04, -0.34), P < 0.001 at 2 months; -0.76 (95%
CI = -1.12, -0.39), P < 0.001 at 4 months; -0.35 (95% CI =
-0.72, 0.01), P = 0.06 at 6 months; -0.17 (95% CI = -0.55,
0.20), P = 0.36 at 9 months; and -0.27 (95% CI = -0.67,
0.12), P = 0.18 at 12 months.
GS and PD scores also showed a more rapid response in
the MTX+PDN group. The GS score MD was -1.78 (95%
CI = -3.66, 0.09), P =0.06 at 6 months and -1.52 (95% CI =
-0.66, 3.71), P = 0.17 at 12 months. The PD score MD was
-1.72 (95% CI = -3.44, -0.01), P = 0.04 at 6 months and
-1.24 (95% CI = -3.21, 0.73), P = 0.21 at 12 months.
Outcome analysis
The frequency of patients achieving clinical remission
(DAS28 < 2.6) was significantly higher in the MTX+PDN
group than in the MTX group: 43/96 (44.8%) versus 25/90
(27.8%) (P = 0.02). The relative risk of clinical remission
was on average 60% higher in the group of combination
therapy when compared with MTX monotherapy (RR =
1.61 (95% CI = 1.08, 2.04)). Globally, SDAI remission was
achieved less frequently than DAS28 remission; however,
MTX+PDN-treated patients had significantly higher prob-
ability of SDAI remission over MTX monotherapy arm at
12 months (30.8% vs. 16%), with a RR of 1.91 (95% CI =
1.08, 3.38; P = 0.01).
Similarly, the probability of reaching PD negativity was
significantly higher in the MTX+PDN group (67/96,
69.8%) than in the MTX group (48/90, 53.3%) (P = 0.04),
with a RR at 12 months of 1.31 (95% CI = 1.04, 1.64). The
combined clinical and US outcome was achieved by 34/96
patients (35.5%) and 14/90 (15.9%) patients in the MTX
+PDN and MTX groups, respectively (P = 0.01), with a RR
of 2.27 (95% CI = 1.31, 3.95). The abovementioned clinical
and imaging outcomes are presented in Figure 3, shown as
the percentages of patients reaching the outcomes at the
end of the follow-up period.
Per-protocol and intention-to-treat analysis results
were almost similar: performance on combination ther-
apy was significantly better over MTX monotherapy for
both clinical and US outcomes. Specifically, the fre-
quency of patients achieving clinical remission (DAS28
< 2.6) was significantly higher in the MTX+PDN group
than in the MTX group with a relative risk (RR) of 1.65
(95% CI = 1.07, 2.54; P = 0.01). Similarly, the probabil-
ities of reaching PD negativity and the combined clinical
and US outcome were significantly higher in the MTX
+PDN group than in the MTX group: RR = 1.34 (95%
CI = 0.99, 1.81; P = 0.05) and RR = 2.49 (95% CI = 1.27,
4.88; P = 0.005), respectively.
Table 1 Baseline demographic, clinical, laboratory and ultrasonographic characteristics of patients according to
therapeutic arm
Methotrexate alone Methotrexate + prednisone P value
n 110 110
Age (years) 62 (51.5 to 72) 57 (45 to 67) 0.06
Sex (female/male) 69/23 71/28 0.60
Symptoms duration (months) 3.48 (2.57 to 5.70) 2.97 (1.93 to 5.10) 0.08
DAS28 5.2 (4.4 to 5.9) 5 (4.2 to 5.9) 0.78
VAS score for pain 51 (46.5 to 79) 55 (40 to 79) 0.64
VAS score for PGA 60 (48 to 75) 60 (47 to 80) 0.61
VAS score for general health status 60 (50 to 72) 56 (50 to 75) 0.92
Swollen joints among 28 joints 8 (4 to 12) 9 (5 to 14) 0.23
Tender joints among 28 joints 8.5 (3.5 to 13) 6 (3 to 12) 0.06
Health Assessment Questionnaire 1 (0.6 to 1.6) 1.1 (0.6 to 1.6) 0.62
Erythrocyte sedimentation rate (mm/hour) 23.5 (12 to 39) 28 (16 to 48) 0.09
C-reactive protein (mg/dl) 0.7 (0.3 to 1.9) 1.2 (0.3 to 2.7) 0.11
US grey scale score 8 (3 to 11) 8 (4 to 12) 0.49
US power Doppler positive 57 (51) 65 (59) 0.27
US power Doppler score 1 (0 to 6) 2 (0 to 7) 0.39
Data presented as median (interquartile range) or n (%). DAS28, disease activity score among 28 joints; VAS, visual analogue scale; PGA, patient’s global
assessment; US, ultrasonography.
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Adverse events
Six adverse events related to GC medication were reported
in six patients; namely, hyperglycaemia (two patients) and
epigastric pain (four patients). Side effects related to MTX
medication - such as nausea, fatigue or slight increase in
liver test function - leading to discontinuation were found
in 10 patients from the MTX group and in six patients in
the PDN co-medication group (P = 0.29).
Discussion
Our data indicate that low-dose oral PDN leads to
higher probability of clinical remission and PD negativ-
ity at 1 year of follow-up in a LDA-driven therapeutic
protocol in early-onset RA patients. We found that the
percentage of subjects achieving LDA at 1 year was not
statistically different between the two treatment arms.
This is not surprising with a treat-to-target therapeutic
approach along with a higher frequency of therapeutic
adjustments in the MTX monotherapy group. Neverthe-
less, GC co-medication gave an earlier and faster clinical
response in terms of DAS28 values over time, with sig-
nificant intergroup difference already detectable after 2
months of treatment, persisting up to 6 months.
The prompt clinical effect of GC co-medication in
early RA has already been reported by several authors
[2-5]. In this regard, Kirwan presented no sustained
clinical advantage on GC co-medication in early RA
patients since the addition of prednisolone to DMARDs
accelerated, but did not enhance, the clinical response
[2]. The clinical benefits on singular clinical parameters
under a very low dose (5 mg/day) of GC co-medication
also did not continue beyond the first year of follow up
in Wassenberg and colleagues’ early RA cohort [5]. Only
Svensson and colleagues found a sustained clinical effect
on low-dose oral prednisolone (7.5 mg/day) as an addi-
tional therapy to DMARDs in early RA patients [7].
Figure 2 Trend over time of measures of clinical subjective and objective variables. Trend over time of measures of clinical subjective and
objective variables along the two treatment arms. Subjective: (A) visual analogue scale (VAS) score for pain. Objective: (B) swollen joint count
over 28 joints (Sw28), (C) tender joint count over 28 joints (Ten28), (D) serum levels of the erythrocyte sedimentation rate (ESR), (E) serum levels
of C-reactive protein (CRP), and (F) absolute mean values of disease activity score among 28 joints (DAS28). *P < 0.05 related to differences
between treatment arms.
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Analysing in our study the trend of each singular clinical
and laboratory parameter over time, we observed only an
initial substantial advantage in adding GC compared with
MTX monotherapy in clinical variables, with no persistent
differences. Most of the benefits associated with GC co-
medication on DAS28 response seems to be explained by
significantly greater, faster and persistent control over
time on acute-phase reactant serum levels (erythrocyte
sedimentation rate and C-reactive protein). This might
also have indirect relevant implications, considering their
prognostic value, especially for C-reactive protein levels
over time, in predicting subsequent structural damage
both in early and established RA [24,25].
The analysis of the US data strengthens this result.
There is evidence that a subgroup of RA patients with
drug-induced sustained remission still have detectable
active subclinical synovitis [10,23]. We analysed the per-
centage of PD negativity in early-onset disease after
achieving DAS28 remission. The analysis revealed that
PD negativity was almost 1.5-fold higher in the PDN co-
medication group than in the MTX monotherapy group
(Additional file 1 shows this in more detail).
Previous studies on the effect of steroid medication on
US measures in RA are scanty and mostly refer to the
favourable short-term effect of a single intravenous,
intra-articular or high-dose oral administration in estab-
lished disease [26-29].
In our study, median US score values significantly
decreased during follow-up in the whole series of
patients, but GC-treated patients presented a trend
toward a greater and more rapid response, so that GC-
treated patients more frequently reached a completely
negative PD status at the end of follow-up. Nevertheless,
in both treatment arms, PD score trends over 6 months
of follow-up were not predictive of the subsequent
achievement of clinical remission. This finding is parti-
cularly important due to the predictive role of PD active
synovitis on relevant disease outcomes [10,22]. As the
persistency of a positive PD signal is the main predictor
of early relapse and radiographic progression in patients
in clinical remission, the higher effect of GC on PD may
explain the long-term beneficial effect on structural
damage.
The particular setting of an inceptional cohort
enabled us to analyse the specific effect of a structured
therapeutic protocol including or not including low-
dose PDN in untreated patients from the onset of the
disease. Furthermore, this study is the first controlled
Figure 3 Patients’ relative frequencies of clinical and/or ultrasonographic outcomes according to treatment group. DAS28R, clinical
remission according to the disease activity score among 28 joints; LDA, low disease activity; MTX, methotrexate monotherapy; MTX+PDN,
methotrexate + prednisone combination therapy; PDneg, power Doppler signal negativity; DAS28R+PDneg, combined outcome of clinical
remission according to disease activity score among 28 joints and power Doppler negativity. *P < 0.05 related to differences between treatment
arms.
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clinical trial exploring the effect of low-dose oral GC
on US outcomes in early RA. The blinded assessment
of US outcome strengthens the validity of these
results.
The present study has some limitations. The sample
size was able to detect only large differences between
the two therapeutic arms, so the study was underpow-
ered for subgroup analyses - such as the specific effect
of GC on the patients achieving clinical remission.
Furthermore, caution should be taken when interpret-
ing the positive results in terms of the combined clini-
cal and US variables, as this combined outcome was
not prespecified. A reduced number of joints (n = 12)
was assessed by US in our study. Although a similar
US evaluation has been extensively applied and vali-
dated in RA, we are aware that a small percentage of
joints with signs of active synovitis might be lost in
this way [30-32]. Moreover, the therapeutic strategy
applied in our study is less aggressive than currently
proposed MTX escalation schedules [33,34]. This char-
acteristic is related to the time when this study was
designed and might have increased the relative effect of
combination therapy over MTX monotherapy. Finally,
the sample size and length of follow-up did not allow
us to measure the effect of GC on rare events, such as
the appearance of new radiographic erosions or some
side effects such as osteoporotic fractures. In relation
to the safety profile, data from our analyses described
few relevant side effects related to low-dose PDN med-
ication, in accordance with a recent meta-analysis pre-
senting a very good safety profile [35,36]. In general,
patients on GC were more likely to withdraw the treat-
ment protocol due to unwillingness to proceed with
GC medication, as also reported in a previous cross-
sectional survey [37].
Conclusion
Our results suggest that in patients with early-onset RA,
the addition of low-dose oral PDN to a MTX back-
ground in the contest of a treat-to-target strategy may
ensure a faster and better control of disease activity,
with higher rates of both clinical remission and PD sig-
nal negativity at 1 year.
To our knowledge, this study shows for the first time
that a greater clinical and subclinical effect of low-dose
GC co-medication over DMARD monotherapy was
demonstrated in early RA patients in a controlled man-
ner. Further data on subsequent structural damage
might confirm and clarify the role of such deeper con-
trol of inflammation on GC therapy. The acceptable
safety profile along with the positive clinical and ima-
ging results should allow us to suggest such a treatment
strategy in the management of early disease.
Additional material
Additional file 1: Figure showing ultrasound images in JPEG format.
Ultrasound images at start of treatment (left side) and after 1 year of
follow-up (right side) in the two treatment arms (MTX alone, first line;
MTX+PDN, second line). RA patients on combination therapy with low-
dose oral prednisone achieved PD negativity significantly more than MTX
monotherapy treated patients at 1 year of follow up.
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